News | July 10, 2014

Interventional Cardiology Practice Expands to Accommodate Younger Patients Seeking Prevention

Orlando Heart Specialists opens 8th location in Dr. Phillips/Windermere Area

July 10, 2014 — Orlando Heart Specialists (OHS) has added an 8th location in southwest Orlando, Fla. According to CEO Kishore Ranadive, the interventional cardiology practice is expanding rapidly to accommodate the growing number of patients wisely seeking to prevent heart problems, rather than waiting until treatment is necessary. The new OHS state-of-the art office in the Dr. Phillips/Windermere area is located at 6735 Conroy Rd.

The additional location is a significant business milestone for OHS, making it among the fastest growing independent medical practices in the region and adding a higher level of convenience for its growing patient base.

Founded in 1997, OHS has grown to become the leading cardiology group in this region, earning national respect through its focus on preventive care and superior patient outcomes. One of six practices nationwide, and the only one in Florida, to achieve certification by the National Committee for Quality Assurance (NCQA), OHS also received the prestigious Bridges to Excellence distinction from the American College of Cardiology for delivering superior patient care.

“This is a proud moment for OHS. Now residents of the Dr. Phillips and Windermere areas will experience why we earn the highest patient satisfaction rates by providing the most positive and caring patient experience possible,” he said.

In addition to the new medical office, OHS also serves patients at its facilities in Altamonte Springs, Orlando, Oviedo, Lake Mary, downtown Orlando, Lake Nona and Apopka. OHS is comprised of board certified cardiovascular specialists dedicated to utilizing the latest technological advances and critical thinking methods in the areas of prevention, intervention, and treatment of heart and vascular disease to help improve the quality of life for their patients. 

For more information: www.OrlandoCardiology.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init